MCID: UVL010
MIFTS: 38

Uveal Disease

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Uveal Disease

MalaCards integrated aliases for Uveal Disease:

Name: Uveal Disease 12 15
Uveal Diseases 76 53 44

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:3480
MeSH 44 D014603
NCIt 50 C26908
SNOMED-CT 68 95678007
UMLS 73 C0042161

Summaries for Uveal Disease

MalaCards based summary : Uveal Disease, also known as uveal diseases, is related to uveitis and phakomatosis cesioflammea. An important gene associated with Uveal Disease is MRAP (Melanocortin 2 Receptor Accessory Protein), and among its related pathways/superpathways are TRAF Pathway and TNF signaling pathway. The drugs Triamcinolone and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, brain and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 The uvea (/�?juːvɪ�?/) (Lat. uva, grape), also called the uveal layer, uveal coat, uveal tract, vascular... more...

Related Diseases for Uveal Disease

Diseases related to Uveal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 uveitis 29.6 IL17A NOD2 RBP3 SAG TNF
2 phakomatosis cesioflammea 10.3 GNA11 GNAQ
3 intraocular melanoma 10.3 GNA11 GNAQ
4 posterior scleritis 10.3 MRAP TNF
5 posterior uveitis 10.2 RBP3 SAG TNF
6 eales disease 10.2 RBP3 SAG TNF
7 skin sarcoidosis 10.2 TNF TNFRSF1B
8 juvenile ankylosing spondylitis 10.2 MRAP TNF TNFRSF1B
9 scleral disease 10.2 MRAP TNF TNFRSF1B
10 pustulosis of palm and sole 10.2 MRAP TNF TNFRSF1B
11 inflammatory bowel disease 20 10.2 MRAP NOD2
12 acute salpingitis 10.2 MRAP TNF TNFRSF1B
13 coccidiosis 10.2 MRAP TLR9 TNF
14 malignant conjunctival melanoma 10.2 GNA11 GNAQ
15 chronic gonococcal salpingitis 10.2 TNF TNFRSF1B
16 palindromic rheumatism 10.2 MRAP TNF TNFRSF1B
17 traumatic glaucoma 10.2 OPTN PHEX
18 encephalitozoonosis 10.2 PEX19 TNF
19 melanomatosis 10.2 GNA11 GNAQ
20 spondyloarthropathy 10.2 IL17A MRAP TNF
21 chronic closed-angle glaucoma 10.2 OPTN PHEX
22 parapsoriasis 10.2 OAT TLR9
23 glaucoma, normal tension 10.2 LOXL1 OPTN
24 stromal keratitis 10.2 IL17A PAX6 TNF
25 iritis 10.2 MRAP TNFRSF1B
26 purulent endophthalmitis 10.2 MRAP OPTN SAG
27 exanthem 10.2 TLR9 TNF TNFRSF1B
28 juvenile glaucoma 10.2 OPTN PAX6 PHEX
29 trichosporonosis 10.2 IL17A TNF
30 rheumatoid lung disease 10.2 IL17A TNF TNFRSF1B
31 central nervous system melanocytic neoplasm 10.2 GNA11 GNAQ OPTN
32 ileocolitis 10.2 NOD2 TNF
33 central nervous system vasculitis 10.2 IL17A TLR9 TNF
34 keratitis, hereditary 10.1 IL17A PAX6 TLR9
35 glaucoma, primary open angle 10.1 LOXL1 OPTN PHEX
36 acute closed-angle glaucoma 10.1 CHM OPTN PEX19
37 chorioretinitis 10.1 MRAP OPTN RBP3 SAG
38 granulomatous dermatitis 10.1 NOD2 TNF TNFRSF1B
39 panophthalmitis 10.1 OPTN SAG
40 extrinsic cardiomyopathy 10.1 IL17A TLR9 TNF
41 adult dermatomyositis 10.1 TLR9 TNF
42 opportunistic mycosis 10.1 IL17A TLR9 TNF
43 autoimmune disease of musculoskeletal system 10.1 IL17A TLR9 TNF
44 autoimmune uveitis 10.1 IL17A RBP3 SAG TNF
45 autoimmune disease of central nervous system 10.1 IL17A TLR9 TNF
46 melkersson-rosenthal syndrome 10.1 NOD2 TNF TNFRSF1B
47 upper respiratory tract disease 10.1 IL17A TLR9 TNF
48 bronchial disease 10.1 IL17A TLR9 TNF
49 peroneal neuropathy 10.1 TNF TNFRSF1B
50 bronchiolitis 10.1 IL17A TLR9 TNF

Graphical network of the top 20 diseases related to Uveal Disease:



Diseases related to Uveal Disease

Symptoms & Phenotypes for Uveal Disease

GenomeRNAi Phenotypes related to Uveal Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.5 OAT
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.5 IL17A
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-15 9.5 IL17A
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-209 9.5 IL17A
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.5 SAG
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.5 GNA11 SAG
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.5 GNA11
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.5 GNA11 IL17A OAT SAG
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.5 IL17A SAG
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.5 GNA11

MGI Mouse Phenotypes related to Uveal Disease:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 BAP1 CHM GNA11 GNAQ IL17A LOXL1
2 growth/size/body region MP:0005378 10.32 BAP1 CHM GNA11 GNAQ IL17A LOXL1
3 mortality/aging MP:0010768 10.28 BAP1 CHM EIF1AX GNA11 GNAQ IL17A
4 cardiovascular system MP:0005385 10.26 BAP1 CHM GNA11 GNAQ LOXL1 PAX6
5 digestive/alimentary MP:0005381 10.24 BAP1 IL17A LOXL1 NOD2 PAX6 PHEX
6 immune system MP:0005387 10.2 BAP1 GNA11 GNAQ IL17A NOD2 OPTN
7 endocrine/exocrine gland MP:0005379 10.18 BAP1 GNA11 GNAQ IL17A PAX6 PHEX
8 craniofacial MP:0005382 10.15 GNA11 GNAQ IL17A PAX6 PHEX TBX3
9 nervous system MP:0003631 10.1 CHM EIF1AX GNA11 GNAQ LOXL1 OAT
10 integument MP:0010771 10.09 BAP1 GNA11 GNAQ LOXL1 OAT PAX6
11 hearing/vestibular/ear MP:0005377 9.97 GNA11 GNAQ LOXL1 OAT PAX6 PHEX
12 muscle MP:0005369 9.91 BAP1 GNA11 GNAQ PAX6 TBX3 TNF
13 renal/urinary system MP:0005367 9.76 GNA11 GNAQ IL17A OAT PAX6 PHEX
14 pigmentation MP:0001186 9.65 CHM GNA11 GNAQ OAT PAX6
15 respiratory system MP:0005388 9.56 BAP1 GNA11 GNAQ IL17A LOXL1 PAX6
16 skeleton MP:0005390 9.28 GNA11 GNAQ IL17A NOD2 PAX6 PHEX

Drugs & Therapeutics for Uveal Disease

Drugs for Uveal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 361)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 124-94-7 31307
2
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
3
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 67-73-2 6215
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
8
Infliximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 170277-31-3
9
Mycophenolic acid Approved Phase 4,Phase 3,Not Applicable 24280-93-1 446541
10
Azathioprine Approved Phase 4,Phase 2,Not Applicable 446-86-6 2265
11
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
12
Timolol Approved Phase 4,Phase 3,Not Applicable 26839-75-8 33624 5478
13
Heparin Approved, Investigational Phase 4,Phase 2 9005-49-6 772 46507594
14
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5311221 5282380
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
17
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
18
Verteporfin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 129497-78-5
19
Povidone Approved Phase 4,Not Applicable 9003-39-8
20
Iodine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 7553-56-2 807
21
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
22
Ganciclovir Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 82410-32-0 3454
23
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
24
Chlorambucil Approved Phase 4 305-03-3 2708
25
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
26
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
27
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
28
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
29
Alfuzosin Approved, Investigational Phase 4 81403-80-7 2092
30
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
31
Travoprost Approved Phase 4,Phase 3,Not Applicable 157283-68-6 5282226
32
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
33
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
34
Difluprednate Approved Phase 4,Phase 3,Phase 2 23674-86-4 443936
35
Fluprednisolone Approved Phase 4,Phase 3,Phase 2 53-34-9
36
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
37
Ofloxacin Approved Phase 4 82419-36-1 4583
38
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
39
Certolizumab pegol Approved Phase 4 428863-50-7
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
41
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
42
Maleic acid Experimental Phase 4,Phase 2 110-16-7 444266
43
Bromfenac Approved July 1997 Phase 4 91714-94-2 60726
44
Lactitol Investigational Phase 4,Not Applicable 585-86-4 3871
45 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
46 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 664)
# Name Status NCT ID Phase Drugs
1 Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization Unknown status NCT02033018 Phase 4 Aflibercept Injection
2 Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) Unknown status NCT01357122 Phase 4
3 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema Unknown status NCT02598869 Phase 4 Triamcinolone Acetonide
4 Ranibizumab for Myopic Neovascularization Unknown status NCT01246089 Phase 4 ranibizumab injection
5 Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
6 Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
7 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
8 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4 methylorednisolone
9 Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis Completed NCT00589628 Phase 4 infliximab;infliximab
10 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed NCT00543296 Phase 4 0.59 mg Fluocinolone Acetonide implant
11 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
12 Assessing Cosopt Switch Patients Completed NCT00273442 Phase 4 timolol maleate;dorzolamide/timolol maleate fixed combination
13 Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties Completed NCT01767012 Phase 4
14 A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery Completed NCT00170729 Phase 4 Prednisolone acetate
15 The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
16 Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification Completed NCT03321253 Phase 4
17 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
18 Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery Completed NCT02137161 Phase 4 Dexamethasone+Tobramycin eye drop;Bromfenac eye drop
19 Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Completed NCT00797992 Phase 4 Injection
20 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
21 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
22 SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia Completed NCT03409250 Phase 4 Ranibizumab, Lucentis
23 Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD Completed NCT03393767 Phase 4 Ranibizumab
24 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
25 Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration. Completed NCT01831947 Phase 4
26 Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab Completed NCT01810042 Phase 4 ranibizumab
27 Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment. Completed NCT01972789 Phase 4 Ranibizumab
28 Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT) Completed NCT01006538 Phase 4 Ranibizumab
29 Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration Completed NCT01628354 Phase 4 Ranibizumab
30 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed NCT01148511 Phase 4 Ranibizumab 0.5 mg
31 Photodynamic Therapy in Occult-Only Lesions (POOL) Completed NCT00135837 Phase 4 Verteporfin for injection
32 Evaluation of Dosing Interval of Higher Doses of Ranibizumab Completed NCT00533520 Phase 4 ranibizumab
33 Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed NCT00504959 Phase 4 ranibizumab
34 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
35 Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU Recruiting NCT03656692 Phase 4 Acthar
36 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
37 Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization Recruiting NCT03042871 Phase 4 0.5mg intravitreal ranibizumab
38 Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Recruiting NCT01939691 Phase 4 Difluprednate;Nepafenac;Prednisolone acetate
39 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
40 Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) Active, not recruiting NCT02320474 Phase 4 Aflibercept
41 Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis Active, not recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
42 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU Active, not recruiting NCT03020992 Phase 4 Certolizumab Pegol
43 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
44 Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Terminated NCT02769702 Phase 4 Acthar
45 Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis Terminated NCT00918554 Phase 4 Methotrexate;Placebo
46 An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Terminated NCT00327470 Phase 4 Pegaptanib Sodium 0.3 mg
47 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy Withdrawn NCT01666236 Phase 4
48 Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) Unknown status NCT00348153 Phase 2, Phase 3 Adalimumab
49 Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks Unknown status NCT00599820 Phase 3 Intravitreal Bevacizumab
50 Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Unknown status NCT00344617 Phase 3 Bevacizumab (tradename: Avastin)

Search NIH Clinical Center for Uveal Disease

Cochrane evidence based reviews: uveal diseases

Genetic Tests for Uveal Disease

Anatomical Context for Uveal Disease

MalaCards organs/tissues related to Uveal Disease:

41
Eye, Brain, Bone, Heart

Publications for Uveal Disease

Articles related to Uveal Disease:

# Title Authors Year
1
Golden retriever cystic uveal disease: a longitudinal study of iridociliary cysts, pigmentary uveitis, and pigmentary/cystic glaucoma over a decade in western Canada. ( 26119416 )
2016
2
Cytokines: their role in uveal disease. ( 9349412 )
1997
3
A-mode echography in the diagnosis of uveal disease. ( 880517 )
1977
4
Methotrexate treatment of uveal disease. ( 5904740 )
1966
5
Retinal lesions associated with uveal disease. I. ( 13372709 )
1956
6
The influence of hypersensitivity on endogenous uveal disease. ( 20288588 )
1947
7
The influence of hypersensitivity on endogenous uveal disease. ( 20279194 )
1946
8
Concerning the Use of Diphtheria Antitoxin in Post-Operative Infections and Acute Uveal Disease. ( 16692610 )
1922

Variations for Uveal Disease

Expression for Uveal Disease

Search GEO for disease gene expression data for Uveal Disease.

Pathways for Uveal Disease

Pathways related to Uveal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.89 GNA11 GNAQ TLR9 TNF TNFRSF1B
2 11.54 NOD2 TNF TNFRSF1B
3 11.31 GNA11 GNAQ TNF
4
Show member pathways
10.46 GNA11 GNAQ
5 10.34 GNAQ TLR9 TNF

GO Terms for Uveal Disease

Cellular components related to Uveal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 photoreceptor outer segment GO:0001750 8.8 GNA11 GNAQ SAG

Biological processes related to Uveal Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of JNK cascade GO:0046330 9.63 NOD2 TLR9 TNF
2 visual perception GO:0007601 9.56 CHM OAT PAX6 RBP3
3 action potential GO:0001508 9.55 GNA11 GNAQ
4 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.54 IL17A NOD2
5 regulation of inflammatory response GO:0050727 9.54 BAP1 NOD2 TNF
6 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.52 TNF TNFRSF1B
7 G protein-coupled acetylcholine receptor signaling pathway GO:0007213 9.51 GNA11 GNAQ
8 maintenance of gastrointestinal epithelium GO:0030277 9.49 NOD2 TLR9
9 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.48 NOD2 TLR9
10 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.43 TLR9 TNF
11 phototransduction, visible light GO:0007603 9.4 GNA11 GNAQ
12 positive regulation of interleukin-6 production GO:0032755 9.33 NOD2 TLR9 TNF
13 entrainment of circadian clock GO:0009649 9.32 GNA11 GNAQ
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.13 NOD2 TLR9 TNF
15 positive regulation of interleukin-8 production GO:0032757 8.8 NOD2 TLR9 TNF

Molecular functions related to Uveal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 guanyl nucleotide binding GO:0019001 8.96 GNA11 GNAQ
2 type 2A serotonin receptor binding GO:0031826 8.62 GNA11 GNAQ

Sources for Uveal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....